Download PDF
Thromb Haemost 1999; 82(02): 742-747
DOI: 10.1055/s-0037-1615906
Research Article
Schattauer GmbH

Hemostatic Gene Expression and Vascular Disease in Obesity: Insights from Studies of Genetically Obese Mice

Fahumiya Samad
1   The Scripps Research Institute, La Jolla, CA, USA
,
David J. Loskutoff
1   The Scripps Research Institute, La Jolla, CA, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

Introduction

Obesity is a major public health problem in Western societies with substantial economic consequences. In the United States alone, over 30% of the population is defined as clinically obese, and thereby, are subject to increased risk for obesity-associated disorders, including cardiovascular disease (CVD), hypertension, insulin resistance, and non-insulin dependent diabetes mellitus (NIDDM).1,2 In spite of the magnitude of this problem, the molecular changes in obesity that promote these conditions are far from resolved. The fact that human obesity is a polygenic disorder with complex environmental and behavioral characteristics has made obesity research one of the more difficult areas of investigation in the medical sciences.1,3 However, recent studies of genetically obese mice and rats have produced breakthroughs in several areas of obesity-related research, primarily because obesity in these animals appears to be monogenic (i.e., to result from mutations in single genes). In this regard, five different genes, all mapped to different chromosomal locations, have been shown to cause distinct syndromes of spontaneous obesity with severe insulin resistance in mice.3 These include the obese (ob), diabetes (db), tubby (tub), lethal yellow (Ay) and fat (fat) mutations. Genes encoding intercellular adhesion molecule 1 (ICAM-1) and the leukocyte integrin αmβ2 (MAC-1) also have been implicated in the regulation of adipose tissue mass.4 These animal studies, together with studies of cultured adipocytes, have provided fundamental new information about the factors and cells that may be responsible for the altered hemostatic balance leading to increased cardiovascular risk in obesity/NIDDM.

In this chapter, we summarize our studies on plasminogen activator inhibitor 1 (PAI-1), tissue factor, and transforming growth factor (TGF)-β expression in obesity, using genetically obese mice as a model. These studies emphasize the key role played by the adipocyte, a cell whose numbers, size, and metabolic activity are grossly altered in obesity/NIDDM. They also implicate multiple cytokines, hormones, and growth factors in the abnormal expression of these and perhaps other hemostatic genes by adipocytes in obesity/NIDDM (Fig. 1). These studies emphasize the key role played by tumor necrosis factor (TNF)-α in the expression of hemostatic genes in this disorder.

 

  • References

  • 1 Finer N. Obesity. Br Med Bull 1997; 53: 229-450.
    CrossrefPubMedGoogle Scholar
  • 2 Nielsen S, Jensen MD. Obesity and cardiovascular disease: is body structure a factor?. Curr Opin Lipidol 1997; 8: 200-204.
    CrossrefPubMedGoogle Scholar
  • 3 Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996; 87: 377-389.
    CrossrefPubMedGoogle Scholar
  • 4 Dong ZM, Gutierrez-Ramos JC, Coxon A, Mayadas TN, Wagner DD. A new class of obesity genes encodes leukocyte adhesion receptors. Proc Natl Acad Sci USA 1997; 94: 7526-7530.
    CrossrefPubMedGoogle Scholar
  • 5 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387.
    PubMedGoogle Scholar
  • 6 Van Meijer M, Pannekoek H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis 1995; 9: 263-276.
    PubMedGoogle Scholar
  • 7 Fearns C, Samad F, Loskutoff DJ. Synthesis and localization of PAI-1 in the vessel wall. In: Van Hinsbergh VWM. ed Vascular Control of Hemostasis. Amsterdam, The Netherlands: Harwood Academic Publishers; 1995: 207-226.
    Google Scholar
  • 8 Lawrence DA, Ginsburg D. Gene expression and function of plasminogen activator inhibitor-1. In: Glas-Greenwalt P. ed Fibrinolysis in Disease: Molecular and Hemovascular Aspects of Fibrinolysis. Boca Raton, FL: CRC Press Inc; 1996: 21-29.
    Google Scholar
  • 9 Carmeliet P, Collen D. Molecular genetics of the fibrinolytic and coagulation systems in haemostasis, thrombogenesis, restenosis and atherosclerosis. Curr Opin Lipidol 1997; 8: 118-125.
    CrossrefPubMedGoogle Scholar
  • 10 Bruckert E, Ankri A, Giral P, Turpin G. Relation between plasminogen activator inhibitor-1 and hepatic enzyme concentrations in hyperlipidemic patients. Thromb Haemost 1994; 72: 434-437.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Friederich PW, Levi M, Biemond BJ, Charlton P, Templeton D, van Zonneveld AJ, Bevan P, Pannekoek H, ten Cate JW. Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits. Circulation 1997; 96: 916-921.
    PubMedGoogle Scholar
  • 12 Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo: tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β. J Clin Invest 1991; 88: 1346-1353.
    CrossrefPubMedGoogle Scholar
  • 13 Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656-660.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Calles-Escandon J, Ballor D, Harvey-Berino J, Ades P, Tracy R, Sobel B. Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction. Am J Clin Nutr 1996; 64: 7-11.
    CrossrefPubMedGoogle Scholar
  • 15 Ailhaud G, Grimaldi P, Négrel R. A molecular view of adipose tissue. Int J Obes Relat Metab Disord 1992; 16: S17-S21.
    PubMedGoogle Scholar
  • 16 Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo: induction by tumor necrosis factor-α and lipopolysaccharide. J Clin Invest 1996; 97: 37-46.
    CrossrefPubMedGoogle Scholar
  • 17 Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 1996; 2: 568-582.
    PubMedGoogle Scholar
  • 18 Samad F, Yamamoto K, Pandey M, Loskutoff D. Elevated expression of transforming growth factor-α in adipose tissue from obese mice. Mol Med 1997; 3: 37-48.
    PubMedGoogle Scholar
  • 19 Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
    CrossrefPubMedGoogle Scholar
  • 20 Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 2: 800-803.
    CrossrefPubMedGoogle Scholar
  • 21 Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fujii S. Elaboration of type-1 plasminogen activator inhibitor from adipocytes: a potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996; 93: 106-110.
    CrossrefPubMedGoogle Scholar
  • 22 Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-867.
    CrossrefPubMedGoogle Scholar
  • 23 Agostino G, Tonoli M, Deorsola B, Chairamonte E, Boschini K, De Sandre G, Manzato F, Cigolini M. PAI-1 release from human adipose tissue is stimulated by TNF-alpha. Thromb Haemost. 1997 Suppl. 749(Abstract)
    PubMedGoogle Scholar
  • 24 Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, Polonsky KS. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 2108-2116.
    PubMedGoogle Scholar
  • 25 Nordt TK, Sawa H, Fujii S, Sobel BE. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995; 91: 764-770.
    CrossrefPubMedGoogle Scholar
  • 26 De Negri F, Morale M, Ferrini L, Ferdeghini M, Dell’Omo G, Pedrinelli R, Carmassi F. Role of insulin in the physiological regulation of PAI-1 expression by endothelial cells. Thromb Haemost 1997; (Suppl) 354a.
    PubMedGoogle Scholar
  • 27 Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabet Med 1993; 10: 27-32.
    CrossrefPubMedGoogle Scholar
  • 28 Nagi DK, Hendra TJ, Ryle AJ, Cooper TM, Temple RC, Clark PMS, Schneider AE, Hales CN, Yudkin JS. The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factor in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 1990; 33: 532-537.
    CrossrefPubMedGoogle Scholar
  • 29 Lormeau B, Aurousseau MH, Valensi P, Paries J, Attali JR. Hyperinsulinemia and hypofibrinolysis: effects of short-term optimized glycemic control with continuous insulin infusion in Type II diabetic patients. Metabolism 1997; 46: 1074-1079.
    CrossrefPubMedGoogle Scholar
  • 30 Alessi MC, Anfosso F, Henry M, Peiretti F, Nalbone G, Juhan-Vague I. Up-regulation of PAI-1 synthesis by insulin and proinsulin in HEP G2 cells but not in endothelial cells. Fibrinolysis 1995; 9: 237-242.
    PubMedGoogle Scholar
  • 31 Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin: a potential risk factor for vascular disease. Circulation 1994; 89: 321-330.
    CrossrefPubMedGoogle Scholar
  • 32 Fujii S, Sobel BE. Induction of plasminogen activator inhibitor by products released from platelets. Circulation 1990; 82: 1485-1493.
    CrossrefPubMedGoogle Scholar
  • 33 Arrants J. Hyperinsulinemia and cardiovascular risk. Heart Lung 1994; 23: 118-122.
    PubMedGoogle Scholar
  • 34 Border WA. Transforming growth factor-beta and the pathogenesis of glomerular diseases. Curr Opin Nephrol Hypertens 1994; 3: 54-58.
    CrossrefPubMedGoogle Scholar
  • 35 Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease: the case for transforming growth factor-beta as a key mediator. Diabetes 1995; 44: 1139-1146.
    PubMedGoogle Scholar
  • 36 Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
    CrossrefPubMedGoogle Scholar
  • 37 Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415.
    CrossrefPubMedGoogle Scholar
  • 38 Hotamisligil GS, Spiegelman BM. Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes 1994; 43: 1271-1278.
    CrossrefPubMedGoogle Scholar
  • 39 Samad F, Uysal KT, Wiesbrock SM, Pandey M, Hotamisligil GS, Loskutoff DJ. Tumor necrosis factor-α is a key component in the obesity-linked elevation of plasminogen activator inhibitor-1. Proc Natl Acad Sci USA. 1999 (in press)
    PubMedGoogle Scholar
  • 40 Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity studies of PAI-1. Arterioscler Thromb Vasc Biol 1998; 18: 1-6.
    CrossrefPubMedGoogle Scholar
  • 41 Carmeliet P, Stassen JM, Schoonjans L, Ream B, Van den Oord JJ, De Mol M, Mulligan RC, Collen D. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 1993; 92: 2756-2760.
    CrossrefPubMedGoogle Scholar
  • 42 Osterud B. Tissue factor: a complex biological role. Thromb Haemost 1997; 78: 755-758.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Meade TW, Ruddock V, Stirling Y, Chakrabarti T, Miller GJ. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-1079.
    CrossrefPubMedGoogle Scholar
  • 44 Bach RR. Initiation of coagulation by tissue factor. Crit Rev Biochem Mol Biol 1988; 23: 339-368.
    PubMedGoogle Scholar
  • 45 Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66: 67-79.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Edgington TS, Dickinson CD, Ruf W. The structural basis of function of the TF×VIIa complex in the cellular initiation of coagulation. Thromb Haemost 1997; 78: 401-405.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 1996; 28: 371-380.
    PubMedGoogle Scholar
  • 48 Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakata T, Miyata T. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol 1995; 15: 1114-1120.
    CrossrefPubMedGoogle Scholar
  • 49 Samad F, Pandey M, Loskutoff DJ. Tissue factor gene expression in the adipose tissues of obese mice. Proc Natl Acad Sci USA 1998; 95: 7591-7596.
    CrossrefPubMedGoogle Scholar